We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
- Authors
Agarwal, Rajiv
- Abstract
Vitamin D receptor agonists (VDRAs) inhibit the renin–angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.
- Subjects
VITAMIN D; ENZYME inhibitors; KIDNEY diseases; PROTEINURIA; RANDOMIZED controlled trials; PATIENTS
- Publication
Kidney International, 2010, Vol 77, Issue 11, p943
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1038/ki.2010.77